Jump to Main Content

ASH Annual Meeting and Exposition

Scientific Workshops

Apply for the Scientific Workshops at the 66th ASH Annual Meeting and Exposition

Apply to conduct a 2024 Scientific Workshop at this year’s annual meeting! The workshops are taking place on Friday, December 6, 2024, and will consist of interactive discussions on the latest scientific developments and engage a diverse audience interested in basic and translational research in specific areas of hematology.

Applications are open until Monday, May 13, 2024, at 11:59 p.m. Pacific time.

Learn More and Apply

The Scientific Workshops are interactive discussions of the latest scientific developments in a particular field of hematology. The following information only corresponds to the 2023 workshops which have been conducted at the ASH 2023 Annual Meeting. Each workshop was conducted in person and simultaneously live-streamed for virtual audiences.

All are welcome to attend each workshop. There is no additional fee, but ASH annual meeting registration is required.


Friday, December 8, 2023,  2:00 p.m. - 5:00 p.m.

Co-Chairs:

Arushi Khurana , MBBS
Mayo Clinic
Rochester,  MN

Alan E. Mast , MD,PhD
Blood Center of Wisconsin
Milwaukee,  WI

This workshop will define the goals for achieving diversity equity and inclusion (DEI) in trials and convene key stakeholders with the objective of fostering collaborations, identifying successful approaches to increasing diversity, and generating tools for evaluation of a representative trial.

Target Audience: Clinicians, clinical investigators, translational investigators, biostatisticians, pharmacologists, pharmacists, regulators, trial sponsors, patient advocates interested in access to clinical trials, inclusion, development, regulations, and approval.

Workshop Schedule


Moderators:

Arushi Khurana , MBBS
Mayo Clinic
Rochester,  MN

Alan E. Mast , MD,PhD
Versiti Blood Research Institute
Milwaukee,  WI

Moderators:

Fangxin Hong , PhD
Pfizer
Boston,  MA

Raul Cordoba , MD, PhD
Fundacion Jimenez Diaz University Hospital
Madrid,  Spain

Speakers:

Arushi Khurana , MBBS
Mayo Clinic
Rochester,  MN
Moderator Introduction

Ruemu E. Birhiray , MD
Hematology Oncology of Indiana, PC
Indianapolis,  IN
DEI in Clinical Trials: Where Are We Now and Where We Should Strive to be?

Thomas E. Witzig , MD
Mayo Clinic
Rochester,  MN
DEI in Clinical Trials - Perceived Versus Actual Barriers and How to Address Them: Clinical Investigator Perspective

Ahmed Abd Almalik Daak , MD,PhD,MSc, DPM/MFPM
Sanofi
Concord,  MA
DEI in Clinical Trials - Perceived Versus Actual Barriers and How to Address Them: Industry Perspective

Moderators:

Thomas E. Witzig , MD
Mayo Clinic
Rochester,  MN

Ruemu E. Birhiray , MD
Hematology Oncology of Indiana, PC
Indianapolis,  IN

Speakers:

Alan E. Mast , MD,PhD
Versiti
Milwaukee,  WI
Moderator Introduction

Nicole Gormley , MD
US Food and Drug Administration
Bethesda,  MD
Goals and Initiatives for a Representative Clinical Trial in Terms of Diversity, Equity and Inclusion: Regulatory Perspective/FDA

Alvaro J. Alencar , MD
Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine
Miami,  FL
Goals and Initiatives for a Representative Clinical Trial in Terms of Diversity, Equity and Inclusion: Co-Operative Group Perspective

Moderators:

Nicole Gormley , MD
US Food and Drug Administration
Bethesda,  MD

Ahmed Abd Almalik Daak , MD,PhD,MSc, DPM/MFPM
Sanofi
Cambridge,  MA

Speakers:

Alan E. Mast , MD,PhD
Versiti
Milwaukee,  WI
Moderator Introduction

Adrian Mckemey , PhD
IQVIA Healthcare Solutions
Kentfield,  CA
Cancer Center Site and Trial Evaluation Tools Enhancing DEI in Trials

Lloryn Hubbard , BA
PPD, Part of Thermo Fisher Scientific
Wilmington,  NC
Community Engagement and Patient Outreach Tools Enhancing DEI in Trials

Raul Cordoba , MD, PhD
Fundacion Jimenez Diaz University Hospital
Madrid,  Spain
Utilizing Digital Health Tools for Enhancing DEI

Speaker:

Alan E. Mast , MD,PhD
Blood Center of Wisconsin
Milwaukee,  WI
Keynote Address: Road Map to Increase DEI in Clinical Trials

Friday, December 8, 2023,  2:00 p.m. - 5:00 p.m.

Co-Chairs:

Piers Blombery , MBBS
Peter Maccallum Cancer Centre
East Melbourne,  VIC, Australia

Torsten Haferlach , MD,PhD
MLL Munich Leukemia Laboratory
Munich,  Germany

Bruno Fattizzo , MD
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
Milano,  Italy

Irina Murakhovskaya , MD
Montefiore Medical Center
Brooklyn,  NY

The ever-changing categorization and increasing biologically driven subcategorization of disease in Classical and Malignant hematological disease demands sophisticated diagnostic tools in order to accurately diagnose and classify disease and improve patient outcomes.

Spanning both molecular and non-molecular approaches, this workshop aims to explore emerging data and concepts around the use of existing and novel diagnostic tools for enhancing diagnosis in Classical and Malignant hematological disease including a focus on advanced testing techniques in immunohematology and transfusion medicine and the expanding role of molecular methodologies.

Target Audience: This workshop is directed at those that are involved in both the delivery of hematology diagnostics as well as those that receive the results. As such the workshop will have broad appeal to a range of specialties and subspecialities within the ASH community including clinical hematologists, hematopathologists, molecular pathologists, medical laboratory scientists, clinical bioinformaticians/computational biologists, genetic counsellors and basic/translational researchers.

Workshop Schedule


Moderator:

Bruno Fattizzo , MD
Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
Milano,  ITA

Moderators:

Bruno Fattizzo , MD
FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
Milano,  Italy

Irina Murakhovskaya , MD
Montefiore Medical Center
Brooklyn,  NY

Speakers:

Karina Yazdanbakhsh , PhD
New York Blood Center Enterprises
New York,  NY
Moderator Introduction

Sandhya R Panch , MD
Fred Hutchinson Cancer Center
Seattle,  WA
Advanced Testing Techniques in Autoimmune Hemolytic Anemia/Role of Molecular Testing in Transfusion Medicine

Sandhya R Panch , MD
Fred Hutchinson Cancer Center
Seattle,  WA
Q+A

Carlo Dufour , MD
Hematology Unit, IRCCS G. Gaslini Children's Hospital
Genova,  Italy
Methods and Reliability of Antineutrophil Antibodies Testing

Carlo Dufour , MD
Hematology Unit, IRCCS G. Gaslini Children's Hospital
Genova,  Italy
Q+A

Hanny Al-Samkari , MD
Massachusetts General Hospital
Cambridge,  MA
Platelet Antibody Testing in Immune Thrombocytopenic Purpura

Hanny Al-Samkari , MD
Massachusetts General Hospital
Cambridge,  MA
Q+A

Moderators:

Piers Blombery , MBBS
Peter Maccallum Cancer Centre
East Melbourne,  VIC, Australia

Torsten Haferlach , MD,PhD
MLL Munich Leukemia Laboratory
Munich,  Germany

Speakers:

Piers Blombery , MBBS
Peter Maccallum Cancer Centre
East Melbourne,  VIC, Australia
Moderator Introduction

Cecilia C.S. Yeung , MD
Fred Hutchinson Cancer Center
Seattle,  WA
Ultra-Deep Sequencing of Chronic Lymphocytic Leukemia to Uncover Dynamics of Resistance

Cecilia C.S. Yeung , MD
Fred Hutchinson Cancer Center
Seattle,  WA
Q+A

Lei Chen
Uppsala University
Uppsala,  Sweden
Ultra-Sensitive Molecular MRD on Flow Cytometer Using Superrca Mutation Assay

Lei Chen
Uppsala University
Uppsala,  Sweden
Q+A

Tamia Nguyen
Peter MacCallum Cancer Centre
Melbourne,  Australia
Whole Genome Sequencing for Deep Characterization of Acute Myeloid Leukemia in Remission

Tamia Nguyen
The University of Melbourne
Parkville,  Australia
Q+A

Christopher C. Oakes , PhD
OSU
Columbus,  OH
Methylation Analysis for Novel Categorization of Mature B-Cell Lymphoma

Christopher C. Oakes , PhD
OSU
Columbus,  OH
Q+A

Moderator:

Piers Blombery , MBBS
Peter Maccallum Cancer Centre
East Melbourne,  VIC, Australia

Speakers:

Imogen Caldwell , FRACP,FRCPA
Auckland City Hospital
Auckland,  Auckland, New Zealand
Case 1

Joseph D. Khoury , MD
University of Nebraska Medical Center
Omaha,  NE
Case 2

Torsten Haferlach , MD,PhD
MLL Munich Leukemia Laboratory
Munich,  Germany
Case 3

Moderators:

Torsten Haferlach , MD,PhD
MLL Munich Leukemia Laboratory
Munich,  Germany

Piers Blombery , MBBS
Peter Maccallum Cancer Centre
East Melbourne,  VIC, Australia

Friday, December 8, 2023,  2:00 p.m. - 5:00 p.m.

Co-Chairs:

Lucy Godley , MD,PhD
Northwestern University
Chicago,  IL

Marcin W. Wlodarski , MD, PhD
St. Jude Children's Research Hospital
Memphis,  TN

Deleterious germline variants conferring susceptibility to hematopoietic malignancies (HM) and bone marrow failure (BMF) are now recognized to be more prevalent than previously assumed. Multiple clinical guidelines now recommend assessing for germline predisposition. The identified genes revealed new molecular pathways important for hematopoiesis and tumorigenesis. However, the mechanisms by which the gene variants cause HMs and BMF remain elusive.

This workshop will feature new research on preclinical model systems and organisms; the intersection between germline predisposition and lymphoid malignancies, solid tumors, and DNA repair pathways; telomeropathies and somatic rescue; discussions regarding standardizing screening globally based on existing clinical recommendations; and predictive prognostic models. Attendees will gain comprehensive insight into this topic both from a scientific and clinical viewpoint and engage in stimulating discussion and debate.

Target Audience:

International investigators actively studying inherited hematopoietic malignancies/bone marrow failure syndromes, trainees, researchers, and clinicians.

Workshop Schedule


Moderator:

Marcin W. Wlodarski , MD, PhD
St. Jude Children's Research Hospital
Memphis,  TN

Moderators:

Jeffery M. Klco , MD, PhD
St. Jude Children's Research Hospital
Memphis,  TN

Marta Santiago , MD
Hospital Universitario y Politécnico La Fe
Valencia,  Spain

Speakers:

Jeffery M. Klco , MD, PhD
St. Jude Children's Research Hospital
Memphis,  TN
Moderator Introduction

Timothy Chlon , PhD
Cincinnati Children's Hospital
Cincinnati,  OH
Functional Analysis of Germline DDX41 Variants Associated with Myelodysplastic Syndrome/Acute Myeloid Leukemia

Timothy Chlon , PhD
Cincinnati Children's Hospital
Cincinnati,  OH
Q + A

Alexandra A. Soukup , PhD
University of Wisconsin School of Medicine and Public Health
Madison,  WI
Gata2 Noncoding Genetic Variation As a Determinant of Hematopoietic Stem/Progenitor Cell Mobilization Efficiency

Alexandra A. Soukup , PhD
University of Wisconsin School of Medicine and Public Health
Madison,  WI
Q + A

Nozomu Kawashima , MD
Cleveland Clinic
Cleveland,  OH
Loss of EFL1 Recapitulates the Phenotype and Molecular and Cell Biology of Loss of SBDS: Insights into the Pathogenesis of Shwachman-Diamond Syndrome

Nozomu Kawashima , MD
Cleveland Clinic
Nagoya,  Japan
Q + A

Senthil V. Bhoopalan , MBBS, PhD
St Jude Children's Research Hospital
Memphis,  TN
Germline Loss-of-Function Mutations in MDM4 Cause DBA Syndrome and Variable Bone Marrow Failure

Senthil V. Bhoopalan , MBBS, PhD
St Jude Children's Research Hospital
Memphis,  TN
Q + A

Luis Batista , PhD
Washington University School of Medicine
St Louis,  MO
Post-Transcriptional Regulation of Ncrna Stability Modulates Hematopoietic Failure in Telomere Biology Syndromes

Luis Batista , PhD
Washington University School of Medicine
St Louis,  MO
Q + A

Moderators:

Jason E. Farrar , MD
University of Arkansas For Medical Sciences
Little Rock,  AR

Christopher R. Reilly , MD
Dana-Farber Cancer Institute, Harvard Medical School
Boston,  MA

Speakers:

Jason E. Farrar , MD
University of Arkansas For Medical Sciences
Little Rock,  AR
Moderator Introduction

Terra L. Lasho , PhD
Mayo Clinic
Rochester,  MN
Adaptive and Maladaptive Somatic Mosaic States in Adult Patients with Telomere Biology Disorders

Christopher M. Sande , MD
Hospital of the University of Pennsylvania
Philadelphia,  PA
The Spectrum and Implications of Clonal Hematopoiesis in Telomere Biology Disorders

Moderators:

Jason E. Farrar , MD
University of Arkansas For Medical Sciences
Little Rock,  AR

Christopher R. Reilly , MD
Dana-Farber Cancer Institute, Harvard Medical School
Boston,  MA

Speakers:

Christopher R. Reilly , MD
Dana-Farber Cancer Institute, Harvard Medical School
Boston,  MA
Moderator Introduction

Alejandro Ferrer , PhD
Mayo Clinic
Rochester,  MN
Molecular and Clinical Implications of U2AF1 Somatic Mosaic States in Telomere Biology Disorders

Simona Colla , PhD
MD Anderson Cancer Center
HOUSTON,  TX
U2AF1 Mutations Drive MDS Pathogenesis in Telomere Biology Disorders

Moderators:

Jason E. Farrar , MD
University of Arkansas For Medical Sciences
Little Rock,  AR

Christopher R. Reilly , MD
Dana-Farber Cancer Institute, Harvard Medical School
Boston,  MA

Speakers:

Jason E. Farrar , MD
University of Arkansas For Medical Sciences
Little Rock,  AR
Moderator Introduction

Kristen E. Schratz , MD
Johns Hopkins University School of Medicine
Baltimore,  MD
Somatic Rescue Mechanisms in the Short Telomere Syndromes and Their Application in Clinical Practice

Lucy C. Fox , BSc,FRACP,FRCPA,MBBS
Peter MacCallum Cancer Centre
Melbourne,  Australia
An Adult Presentation of a Telomere Biology Disorder with Current Challenges Regarding Fertility Management

Moderators:

Christopher N. Hahn , PhD
Molecular Pathology Research Laboratory, Centre for Cancer Biology
Adelaide,  Australia

Grace Christou , MD,MSc,FRCPC
The Ottawa Hospital
Ottawa,  ON, Canada

Speakers:

Christopher N. Hahn , PhD
University of South Australia
Adelaide,  SA, Australia
Moderator Introduction

Mary Armanios , MD
Johns Hopkins University School of Medicine
Baltimore,  MD
Inherited Hematologic Malignancies in the Long Telomere Syndrome

Mary Armanios , MD
Johns Hopkins University School of Medicine
Baltimore,  MD
Q + A

Harry Layton Lesmana , MD
Cleveland Clinic
Cleveland,  OH
Germline POT1 Mutation Predisposing to Pediatric Burkitt Leukemia

Harry Layton Lesmana , MD
Cleveland Clinic
Cleveland,  OH
Q + A

Helen D. Reed , MD
Dana Farber Cancer Institute
Boston,  MA
Increased Incidence of Lymphoid Malignancy in Shwachman-Diamond Syndrome: A Study from the North American SDS Registry

Helen D. Reed , MD
Dana Farber Cancer Institute
Boston,  MA
Q + A

Richa Sharma , MD
St Jude Children's Research Hospital
Memphis,  TN
Incidence and Prognosis of Lymphoid Malignancies in Ataxia Telangiectasia

Richa Sharma , MD
St Jude Children's Research Hospital
Memphis,  TN
Q + A

Lisa J. McReynolds , MD, PhD
National Cancer Institute
Rockville,  MD
Most Fanconi Anemia Heterozygotes Are Not Aa Increased Cancer Risk: A Genome-First Discovehr Cohort Population Study

Lisa J. McReynolds , MD, PhD
National Cancer Institute
Rockville,  MD
Q + A

Moderators:

Maria N. Spangenberg , MD
Hospital de Clinicas
Montevideo,  URY

Kirsten M. Williams , MD
Emory University
Atlanta,  GA

Speakers:

Maria N. Spangenberg , MD
Hospital de Clinicas
Montevideo,  URY
Moderator Introduction

Margaret Williams , MD
University of Utah Health
Salt Lake City,  UT
Somatic Pathogenic UBA1 Mutations Predispose Male Patients to Myeloid Neoplasms

Margaret Williams , MD
University of Utah Health
Salt Lake City,  UT
Q + A

Jill de Jong , MD, PhD
University of Chicago
Chicago,  IL
Retrospective Genetic Testing for Pediatric Patients with Presumed Idiopathic Aplastic Anemia Reveals Inherited Bone Marrow Failure Syndromes

Jill de Jong , MD,PhD
University of Chicago
Chicago,  IL
Q + A

Urpu Salmenniemi
Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki
Helsinki,  Finland
Allogeneic Hematopoietic Stem Cell Transplant in ERCC6L2 Patients

Urpu Salmenniemi
Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki
Helsinki,  Finland
Q + A

Daniel I. Nathan , MD
Icahn School of Medicine at Mount Sinai
New York,  NY
Importance of Context in Clonal Progression of TP53 Mutations in Mosaicism and Clonal Hematopoiesis

Daniel I. Nathan , MD
Icahn School of Medicine at Mount Sinai
New York,  NY
Q + A

Panagiotis Baliakas , MD
Uppsala University
Uppsala,  Sweden
Integrating Germline Investigation for Hematologic Malignancies in the Clinical Setting: The Swedish Experience

Panagiotis Baliakas , MD
Uppsala University
Uppsala,  Sweden
Q + A

Moderator:

Lucy Godley , MD,PhD
Northwestern University
Chicago,  IL

Friday, December 8, 2023,  2:00 p.m. - 5:00 p.m.

Co-Chairs:

Ashley E Rosko , MD
The Ohio State University
Columbus,  OH

Megan Weivoda , PhD
Mayo Clinic
Rochester,  MN

Hematologic disorders disproportionately affect older adults; despite this, our understanding of the implications of age on the pathogenesis and treatment of these diseases remains limited. The geroscience field is actively investigating clinical markers and scores to aid in distinguishing biological and chronological aging. Biological aging assessments for hematologic disease will be crucial for understanding and appropriately treating aging patients, along with facilitating the translation of emerging new immune therapies, as well as potential microbial and dietary interventions, for aging adults. There is also potential opportunity to target aging mechanisms to treat hematologic diseases.

Target Audience:

Laboratory-based scientists, clinical/translational investigators, and early career investigators with an interest in aging and hematology (malignant and classical).

Workshop Schedule


Moderators:

Megan Weivoda , PhD
Mayo Clinic
Rochester,  MN

Ashley E Rosko , MD
The Ohio State University
Columbus,  OH

Moderators:

Shakira J. Grant , MBBS,MSCR
ASH/AAAS Congressional Science and Policy Fellow
Washington,  DC

Martine Extermann , MD
Moffitt Cancer Center
Tampa,  FL

Speakers:

Shakira J. Grant , MBBS,MSCR
ASH/AAAS Science and Policy Fellow
Washington,  DC
Moderator Introduction

Rebecca S. Hesterberg , PhD
Moffitt Cancer Center
Tampa,  FL
Lymphoma Accelerates Aging Phenotypes and Epigenetic States in Adaptive Immune Cells

Charlotte Pawlyn , MBBChir, PhD
The Institute of Cancer Research
London,  United Kingdom
Translational Research, Including Molecular Biomarkers of Aging, from the UK-MRA Frailty Adjusted “Fitness” Study

Kah Poh (Melissa) Loh , MD
James P Wilmot Cancer Institute
Rochester,  NY
Epigenetic Age and Exercise in Older Adults with Myeloid Neoplasms

Moderators:

Rebecca Olin , MD
University of California San Francisco
San Francisco,  CA

Ciara Louise L. Freeman , MD, PhD, MSc
Moffitt Cancer Center
Tampa,  FL

Speakers:

Ciara Louise L. Freeman , MD, PhD, MSc
Moffitt Cancer Center
Tampa,  FL
Moderator Introduction

Francesco Maura , MD
University of Miami
PALMETTO BAY,  FL
Leveraging Genomics to Predict Treatment Selection in Older Adults Treated with Immunotherapy

Othman S Akhtar , MD
Medical College of Wisconsin
Milwaukee,  WI
Immune Nutritional Score and Novel Cytokines As Predictors of Toxicity in Patients Treated with CAR-T Therapy

Roshini S. Abraham , PhD
Nationwide Childrens Hospital
Columbus,  OH
Immune Ageing and Immunotherapies: Age Is More Than a Number!

Moderators:

Andrew Artz , MD,MS
City of Hope
Duarte,  CA

Richard J. Lin , MD,PhD
Memorial Sloan Kettering Cancer Center
New York,  NY

Speakers:

Andrew Artz , MD,MS
City of Hope
Duarte,  CA
Moderator Introduction

Christopher R D'Angelo , MD
University of Nebraska Medical Center
Bennington,  NE
The Role of the Gut Microbiome in the Development of Chronic Lymphocytic Leukemia

Margaret Goodell , PhD
Baylor College of Medicine
Houston,  TX
The Role of the Microbiome in the Development of Clonal Hematopoiesis

Jenny Paredes Sanchez , PhD
Memorial Sloan Kettering Cancer Center
New York,  NY
Correlations of Dietary Fiber with Intestinal Microbiome and Outcomes in Allogeneic Hematopoietic Cell Transplantation

Borja Gil Garcia
Albacete University Hospital
Albacete,  Spain
Impact of Diet in Nutritional Metabolomics and Frailty in Older Patients with Multiple Myeloma

Moderators:

Robert Signer , PhD
Moores Cancer Center
La Jolla,  CA

Heidi Klepin , MD
Wake Forest University School of Medicine
Winston Salem,  NC

Speakers:

Heidi Klepin , MD
Wake Forest University School of Medicine
Winston Salem,  NC
Moderator Introduction

Francesca Cottini , MD
The Ohio State University
Columbus,  OH
The Role of CD56 Signaling in the Response to Oxidative Stress in Multiple Myeloma

Marta Diaz-delCastillo , PhD
Aarhus University
Aarhus,  DNK
Changes in Bone Marrow Adipose Tissue Signaling in the Progression of Pre-Malignant Monoclonal Gammopathies

Jayna J Mistry , PhD
The Jackson Laboratory
Bar Harbor,  ME
Clonal Hematopoiesis Drives Cellular Senescence in Bone Marrow Stroma to Accelerate Progression to Leukemia

Moderators:

Megan Weivoda , PhD
Mayo Clinic
Rochester,  MN

Ashley E Rosko , MD
The Ohio State University
Columbus,  OH

Friday, December 8, 2023,  2:00 p.m. - 5:00 p.m.

Co-Chairs:

Aaron D. Schimmer , MD
Princess Margaret Hospital, University of Toronto
Toronto,  ON, Canada

Marina Y. Konopleva
Albert Einstein College of Medicine
Bronx,  NY

A subset of blood cancer cells are under increased mitochondrial stress through mechanisms such as oxidative damage, altered metabolism, hypoxia, mitochondrial protein damage and protein misfolding. Using evolutionary conserved pathways including anti-oxidants, anti-apoptotic pathways, proteases, and protein chaperones, mitochondria have developed mechanisms to survive amidst these stressors.

Target Audience: Investigators studying mitochondrial stress, pathways and metabolism from model organisms to patients, including cancer biologists and clinical trialists.

Workshop Schedule


Moderators:

Aaron D. Schimmer , MD
Princess Margaret Hospital, University of Toronto
Toronto,  ON, Canada

Marina Y. Konopleva
Albert Einstein College of Medicine
Bronx,  NY

Moderator:

Keisuke Ito , MD,PhD
Albert Einstein College of Medicine
Bronx,  NY

Speakers:

Keisuke Ito , MD,PhD
Albert Einstein College of Medicine
Bronx,  NY
Moderator Introduction

Aaron D. Schimmer , MD
Princess Margaret Hospital, University of Toronto
Toronto,  ON, Canada
Mitochondrial Unfolded Protein Response - Survival Mechanism for Worms and Achilles Heel for AML

Aaron D. Schimmer , MD
Princess Margaret Hospital, University of Toronto
Toronto,  ON, Canada
Q+A

Britta Will , PhD
Albert Einstein College of Medicine/Montefiore Medical Center
Bronx,  NY
Iron Homeostasis Dependent Regulation of Hematopoietic Stem Cell Fate

Britta Will , PhD
Albert Einstein College of Medicine/Montefiore Medical Center
Bronx,  NY
Q+A

Moderator:

Jo Ishizawa , MD,PhD
The University of Texas MD Anderson Cancer Center
Houston,  TX

Speakers:

Jo Ishizawa , MD,PhD
The University of Texas MD Anderson Cancer Center
Houston,  TX
Moderator Introduction

Natalia Baran , MD, PhD, MSc
The University of Texas MD Anderson Cancer Center
Houston,  TX
Targeting Mitochondria Via Glutamine Pathway Inhibition As a Key Metabolic Vulnerability in Hematological Malignancies

Natalia Baran , MD, PhD, MSc
The University of Texas MD Anderson Cancer Center
Houston,  TX
Q+A

Iannis Aifantis , PhD
New York University, Grossman School of Medicine
New York,  NY
The Role of MFN2-Mediated Mitochondrial Dynamics in BH3 Mimetics Resistance

Iannis Aifantis , PhD
New York University, Grossman School of Medicine
New York,  NY
Q+A

Moderator:

Marina Y. Konopleva
Albert Einstein College of Medicine
Bronx,  NY

Speakers:

Marina Y. Konopleva
Albert Einstein College of Medicine
Bronx,  NY
Moderator Introduction

Timothy S Pardee , MD, PhD
Comprehensive Cancer Center of Atrium Health Wake Forest Baptist
Winston-Salem,  NC
Targeting Mitochondrial Metabolism in Acute Myeloid Leukemia, Lessons Learned

Timothy S Pardee , MD, PhD
Wake Forest University
Winston-Salem,  NC
Q+A

Michael Andreeff , MD PhD
The University of Texas MD Anderson Cancer Center
Houston,  TX
Mitochondrial Ferroptosis in Acute Myeloid Leukemia

Michael Andreeff , MD PhD
The University of Texas MD Anderson Cancer Center
Houston,  TX
Q+A

Moderators:

Aaron D. Schimmer , MD
Princess Margaret Hospital, University of Toronto
Toronto,  ON, Canada

Marina Y. Konopleva
Albert Einstein College of Medicine
Bronx,  NY

Friday, December 8, 2023,  2:00 p.m. - 5:00 p.m.

Co-Chairs:

Patricia Ernst , PhD
University of Colorado Anschutz Medical Campus
Aurora,  CO

Ulrich Steidl , MD, PhD
Albert Einstein College of Medicine-Montefiore Health System
Bronx,  NY

The workshop will cover the basic science of myeloid development or pathophysiology and there will be no presentations on clinical/treatment strategies. The research that will be presented will utilize the tools of molecular biology, biochemistry, bioinformatics, and animal models to address these topics. Talks will feature emerging data from cutting-edge research groups that is expected to have a broad and lasting impact on the field. The workshop is designed to be an interactive discussion of primary data after very brief introductions.

Target Audience:

Laboratory/translational investigators, including trainees, with many interests surrounding normal and pathological myeloid/stem cell biology.

Workshop Schedule


Moderators:

Patricia Ernst , PhD
University to University of Colorado Anschutz Medical Campus
Denver,  CO

Ulrich Steidl , MD, PhD
Albert Einstein College of Medicine-Montefiore Health System
Bronx,  NY

Moderator:

Eric M. Pietras , PhD
University to University of Colorado Anschutz Medical Campus
Denver,  CO

Speakers:

Eric M. Pietras , PhD
University to University of Colorado Anschutz Medical Campus
Denver,  CO
Moderator Introduction

Masayuki Yamashita , MD,PhD
The University of Tokyo
Tokyo,  TKY, Japan
The Role of the Necroptosis Pathway in Hematopoietic Stem Cell Aging

Masayuki Yamashita , MD,PhD
The University of Tokyo
Tokyo,  TKY, Japan
Q+A

Michael D. Milsom , PhD
DKFZ, Heidelberg, Germary
Heidelberg,  DEU
During Aging, the Integrity of the Hematopoietic Stem Cell Genome Is Maintained By Cellular Dormancy, Not Apoptosis

Michael D. Milsom , PhD
HI-STEM Ggmbh
Heidelberg,  DEU
Q+A

Luisa Cimmino , PhD,BSc
University of Miami-Miller School of Medicine
Miami,  FL
The Role of One-Carbon Metabolism in the Pathogenesis of Myeloid Malignancy

Luisa Cimmino , PhD,BSc
University of Miami-Miller School of Medicine
Miami,  FL
Q+A

Stephanie Z. Xie , PhD
University Health Network
Toronto,  ON, Canada
Inflammatory Memory in Human Hematopoietic Stem Cell: A Double-Edged Sword

Stephanie Z. Xie , PhD
University Health Network
Toronto,  ON, Canada
Q+A

Moderator:

Claudia Lengerke , MD
University Hospital Tuebingen
Tübingen,  Germany

Speakers:

Claudia Lengerke , MD
University Hospital Tuebingen
Tuebingen,  Germany
Moderator Introduction

Susumu Goyama , MD
The University of Tokyo
Tokyo,  Japan
SETDB1 As a Therapeutic Target in Monocytic Acute Myeloid Leukemia

Susumu Goyama , MD
The University of Tokyo
Tokyo,  Japan
Q+A

David Sykes , MD, PhD
Massachusetts General Hospital
Boston,  MA
An Unexpected Spontaneous Mutation Results in a New Mouse Model of Thrombopoietin Deficiency

David Sykes , MD, PhD
The Massachusetts General Hospital
Boston,  MA
Q+A

Olaia M. Naveiras , MD, PhD
Laboratory of Regenerative Hematopoiesis
Lausanne,  CHE
Lessons from Adiposity: Adrenal Extramedullary Hematopoiesis As an Inducible Model of the Adult Hematopoietic Niche

Olaia M. Naveiras , MD, PhD
Laboratory of Regenerative Hematopoiesis
Lausanne,  CHE
Q+A

Trista E. North , PhD
Boston Children's Hospital, Harvard Medical School
Boston,  MA
Biomechanical Activation of Yap/Taz Signaling Drives Developmental Hematopoietic Stem and Progenitor Cell Production over Differentiation

Trista E. North , PhD
Boston Children's Hospital, Harvard Medical School
Boston,  MA
Q+A

Moderator:

Zuzana Tothova , MD,PhD
Dana-Farber Cancer Institute
Boston,  MA

Speakers:

Zuzana Tothova , MD,PhD
Dana-Farber Cancer Institute
Boston,  MA
Moderator Introduction

Jennifer J. Trowbridge , PhD
The Jackson Laboratory
Bar Harbor,  ME
Elevated Functional Hematopoietic Stem and Progenitor Cells in the Peripheral Blood of Granulocyte – Colony Stimulating Factor Mobilized Dnmt3a-Mutant Mice

Jennifer J. Trowbridge , PhD
The Jackson Laboratory
Bar Harbor,  ME
Q+A

Thomas Mercher , PhD
Institut Gustave Roussy
Villejuif,  France
Early Steps of ETO2-GLIS2 Leukemogenesis Using Novel Human Cell-Based Models

Thomas Mercher , PhD
Institut Gustave Roussy
Villejuif,  France
Q+A

Craig M Forester , MD,PhD
Children's Hospital of Colorado
Aurora,  CO
A Novel Bone Marrow Failure Mutation Results in Altered Taspase1 Substrate Specificity

Craig M Forester , MD,PhD
Children's Hospital of Colorado
Aurora,  CO
Q+A

Lynn H Lee , MD
Cincinnati Children's Hospital Medical Center
Cincinnati,  OH
Igf2bp1 Is Essential for Eto2/Glis2 Leukemogenesis Via Stabilization of Primitive Hematopoietic Transcriptional Programs

Lynn H Lee , MD
Cincinnati Children's Hospital Medical Center
Cincinnati,  OH
Q+A

Moderator:

Kathrin M. Bernt , MD
Children's Hospital of Philadelphia
Philadelphia,  PA

Speakers:

Kathrin M. Bernt , MD
Children's Hospital of Philadelphia
Philadelphia,  PA
Moderator Introduction

Bruno Di Stefano , PhD,MSc,BSc
Baylor College of Medicine
Houston,  TX
Hijacking of RNA Sequestration in Cytoplasmic Condensates Promotes Leukemogenesis

Bruno Di Stefano , PhD,MSc,BSc
Baylor College of Medicine
Houston,  TX
Q+A

Hanna Mikkola , MD PhD
University of California Los Angeles
Los Angeles,  CA
MLLT3 Long and Short Isoforms Balance Human Hematopoietic Stem Cell Fate Decisions

Hanna Mikkola , MD PhD
University of California Los Angeles
Los Angeles,  CA
Q+A

Andrew Volk , PhD
Cincinati Childrens Hospital Medical Center
Cincinnati,  OH
Mechanisms Driving Therapy-Induced Plasticity in Acute Myeloid Leukemia

Andrew Volk , PhD
Cincinati Childrens Hospital Medical Center
Cincinnati,  OH
Q+A

Julia E Maxson , PhD
Oregon Health and Science University
Portland,  OR
Context-Specific Effects of ASXL1 Mutations on Myeloid Differentiation

Julia E Maxson , PhD
Oregon Health and Science University
Portland,  OR
Q+A

Moderators:

Patricia Ernst , PhD
University of Colorado Anschutz Medical Campus
Aurora,  CO

Ulrich Steidl , MD, PhD
Albert Einstein College of Medicine-Montefiore Health System
Bronx,  NY

Friday, December 8, 2023,  2:00 p.m. - 5:00 p.m.

Co-Chairs:

Lisa Baumann Kreuziger , MD,MS
Versiti
Menomonee Falls,  WI

Jeffrey I. Zwicker , MD
Beth Israel Deaconess Medical Center Harvard Medical School
Boston,  MA

Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer and cancer patients are the highest risk group for developing VTE. Despite considerable epidemiologic research, the mechanism of thrombosis in cancer is poorly understood.

This workshop will provide a unique forum to discuss mechanisms of thrombosis in hematologic malignancies, a topic that bridges malignant and classical hematology. Specifically, sessions will address gaps in knowledge and ongoing investigations into mechanisms of thrombosis in myeloproliferative neoplasms and solid tumors. There will also be an exploration of (1) mechanisms of thrombosis in brain tumors and the role that neutrophil extracellular traps play in the development of cancer-associated thrombosis; as well as (2) thrombosis in myeloproliferative neoplasms.

Target Audience: Junior and senior investigators conducting basic to clinical research and specifically seeking to understand the mechanisms of thrombosis in cancer patients and how thrombosis may influence the progression of cancer.

Workshop Schedule


Moderators:

Lisa Baumann Kreuziger , MD,MS
Medical College of Wisconsin
Milwaukee, 

Jeffrey I. Zwicker , MD
Memorial Sloan Kettering Cancer Center
New York,  NY

Moderator:

Stephanie Lee , MD, MSc, FRCPC
University of Toronto/St. Michael's Hospital
Toronto,  Canada

Speakers:

Stephanie Lee , MD, MSc, FRCPC
University of Toronto/St. Michael's Hospital
Toronto,  Canada
Moderator Introduction

Jorge Di Paola , MD
Washington University in St Louis
St Louis,  MO
Aberrant Platelet Activity in Myeloproliferative Neoplasms

Sarah Kelliher
Mater Misericordiae University Hospital
Dublin,  Ireland
Platelet Proteome in Myeloproliferative Neoplasms

Josef T. Prchal , MD
Huntsman Cancer Institute, University of Utah
Salt Lake City,  UT
KLF2 and Hypercoagulability in Myeloproliferative Neoplasms

Anand Pabmanabhan , MBBS,PhD
Mayo Clinic
Rochester,  MN
PF4 Antibodies in Monoclonal Gammopathy of Thrombotic Significance

Moderator:

Sol Schulman , MD, PhD
Beth Israel Deaconess Medical Center, Harvard Medical School
Boston,  MA

Speakers:

Sol Schulman , MD, PhD
Beth Israel Deaconess Medical Center, Harvard Medical School
Boston,  MA
Moderator Introduction

Vahid Afshar-Kharghan , MD
M.D. Anderson Cancer Center
Houston,  TX
Circulating Mitochondria and Venous Thromboembolism in Glioma

Araci Rondon , PhD
Leiden University Medical Center
Leiden,  Netherlands
Thrombosis-on-a-Chip and Glioma Thrombosis

Simon Mantha , MD,MPH
Memorial Sloan Kettering Cancer Center
New York,  NY
Somatic Mutations in Glioma Associated with Venous or Arterial Thrombosis

Moderator:

Ofir Wolach , MD
Institute of Hematology, Davidoff Cancer Center
Petah Tikva,  Israel

Speakers:

Ofir Wolach , MD
Institute of Hematology, Davidoff Cancer Center
Petah Tikva,  Israel
Moderator Introduction

Britney Niemann , MD
West Virginia University
Morgantown,  WV
Role of Neutrophil Extracellular Traps in Pancreatic Cancer

Axel Rosell , MD,PhD
Karolinska Institutet
Stockholm,  Sweden
Evaluating Neutrophil Extracellular Trap Biomarkers in Cancer Associated Thrombosis

Ingrid Pabinger , MD
Medical University of Vienna
Vienna,  Austria
Neutrophil Subpopulations Implicated in Neutrophil Extracellular Trap Formation and Thrombosis

Henny H. Billett , MD
Albert Einstein College of Medicine
Bronx,  NY
Identification of Neutrophil Extracellular Traps Using Routine Hematology Autoanalyzer's

Moderators:

Lisa Baumann Kreuziger , MD,MS
Versiti
Menomonee Falls,  WI

Jeffrey I. Zwicker , MD
Beth Israel Deaconess Medical Center Harvard Medical School
Boston,  MA

Friday, December 8, 2023,  2:00 p.m. - 5:00 p.m.

Co-Chairs:

Panagiotis Ntziachristos , PhD
Ghent University
Corneel Heymanslaan 10,  Ghent, Belgium

Daniel T. Starczynowski , PhD
University of Cincinnati College of Medicine
Cincinnati,  OH

Christina Glytsou , PhD
Rutgers University,
Newark,  NJ

Resistance to therapy is an unmet need in the treatment of blood disorders, as mechanisms of resistance are relatively understudied.

The workshop will cover aspects of resistance to therapy in blood disorders, focusing on non-genetic molecular mechanisms such as epigenetic, epitranscriptomic and metabolic aspects and their potential interaction with genetic alteration. Platforms allowing the comparison between diagnosis and relapsed samples, or relapse-promoting mechanisms existing at diagnosis and potential therapeutic intervention will be discussed.

Target Audience: Basic and translational research-focused investigators from both academia and industry interested in understanding and targeting resistance to therapy. Clinicians treating aggressive leukemias and interested in integrating latest research developments with current frontline therapies such as chemotherapy or immunotherapy.

Workshop Schedule


Moderator:

Panagiotis Ntziachristos , PhD
Ghent University
Corneel Heymanslaan 10,  Ghent, Belgium

Moderators:

Coraline Mlynarczyk , PhD
Weill Cornell Medicine
New York,  NY

Panagiotis Ntziachristos , PhD
Ghent University
Corneel Heymanslaan 10,  Ghent, Belgium

Speakers:

Panagiotis Ntziachristos , PhD
Ghent University
Corneel Heymanslaan 10,  Ghent, Belgium
Moderator Introduction

Mark A. Dawson , MBBS,PhD,FRACP,FRCPA
Peter Maccallum Cancer Centre
Melbourne,  VIC, Australia
Clonal Mechanisms of Adaptation to Therapeutic Pressure in Acute Leukemia

Jonathan D. Licht , MD
University of Florida
Gainesville,  FL
NSD2 and Glucocorticoid Resistance in Acute Lymphoblastic Leukemia

Manel Esteller , MD
Josep Carreras Leukaemia Research Institute
Badalona,  Spain
Single-Cell Multiomics in Myelodysplastic Syndromes and Acute Myeloid Leukemia Upon Treatment with Hypomethylating Agents

Moderator:

Eric Wang , PhD
The Jackson Laboratory For Genomic Medicine
Farmington,  CT

Speakers:

Eric Wang , PhD
The Jackson Laboratory For Genomic Medicine
Farmington,  CT
Moderator Introduction

Konstantinos Tzelepis , PhD
University of Cambridge
Cambridge,  United Kingdom
Overcoming Therapy Resistance in Acute Myeloid Leukemia Using Novel Epitranscriptomic Modalities

Coraline Mlynarczyk , PhD
Weill Cornell Medicine
New York,  NY
Accelerated MYC Protein Translation Kinetics By BTG1 Mutation in Aggressive, Difficult to Treat Diffuse Large B Cell Lymphomas

Jason Xiaojun Cheng , MD,PhD
University of Chicago
Chicago,  IL
RNA:m5C Methyltransferases and RNA Epigenetics-Mediated Drug Resistance in Leukemia

Moderator:

Daniel T. Starczynowski , PhD
University of Cincinnati
Cincinnati,  OH

Speakers:

Daniel T. Starczynowski , PhD
University of Cincinnati
Cincinnati,  OH
Moderator Introduction

Daniel T. Starczynowski , PhD
University of Cincinnati
Cincinnati,  OH
Targeting Immune/Inflammatory-Related Pathways in Myeloid Malignancies

Eirini Papapetrou, MD, Phd , MD,PhD
Icahn School of Medicine at Mount Sinai
New York,  NY
N/KRAS-Mutant Acute Myeloid Leukemia Stem Cells Originate from Committed Myelomonocytic Progenitors and Drive Clinical Resistance to Venetoclax

Li Du , PhD
Judy and Bernard Briskin Center for Multiple Myeloma Research, Beckman Research Institute City of Hope
Duarte,  CA
Targeting Sumoylation Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment

Moderator:

Christina Glytsou , PhD
Rutgers University
Piscataway,  NJ

Speakers:

Christina Glytsou , PhD
Rutgers University
Piscataway,  NJ
Moderator Introduction

Christina Glytsou , PhD
Rutgers University
Piscataway,  NJ
Mitochondrial Dynamics Adaptations in BH3-Mimetics Resistant Acute Myeloid Leukemia

Ravi Majeti , MD
Stanford University School of Medicine
Stanford,  CA
Synthetic Lethal Metabolic Dependencies in IDH1-Mutant Acute Myeloid Leukemia

Courtney L Jones , PhD
Cincinnati Children's Hospital Medical Center
Cincinatti,  OH
Targeting Polyamine Metabolism in Leukemia Stem Cells

Moderator:

Daniel T. Starczynowski , PhD
University of Cincinnati
Cincinnati,  OH

Friday, December 8, 2023,  2:00 p.m. - 5:00 p.m.

Co-Chairs:

Maher K. Gandhi , MBChB, PhD
Mater Research, University of Queensland
Brisbane,  QLD, Australia

Rayne Rouce , MD
Texas Children's Hospital
Houston,  TX

Keri Toner , MD
Children's National Hospital
Washington,  DC

Helen Elisabeth Heslop
Baylor College of Medicine
Houston,  TX

The pandemic, along with recent developments in our understanding of the pathogenesis of viral-associated lymphoproliferative disorders (LPDs), have sparked renewed interest in the topic of viruses in hematology. Those with transplant induced, inherited, iatrogenic or AIDS related immunosuppression, along with pediatric and elderly populations are at particular risk. Geographic and ethnic differences are marked. As exogenous viruses are relatively well-characterized, they have long represented a promising arena for precision oncology. Advances in cellular therapy, that can potentially be given in combination or in sequence with other novel strategies, has meant that the potential of anti-viral adoptive immunotherapy has started to be realized. With a focus on EBV, CMV, SARS-CoV-2, VZV and BK viruses, the workshop will cover relevant changes to the WHO / ICC hematopoietic classifications, major discoveries and developments in relation to viral biology and immunology; and provide emerging data on autologous and third-party virus-specific T-cells.

Target Audience: Basic laboratory-based molecular/immunological and viral scientists, Clinicians interested in latest developments, and those with an interest in immunotherapy.

Workshop Schedule


Moderator:

Maher K. Gandhi , MBChB, PhD
Mater Research, University of Queensland
Brisbane,  QLD, Australia

Moderator:

Helen Elisabeth Heslop
Baylor College of Medicine
Houston,  TX

Speakers:

Helen Elisabeth Heslop
Baylor College of Medicine
Houston,  TX
Moderator Introduction

Elaine S. Jaffe , MD
National Cancer Institute
Bethesda,  MD
An Update on Classification

Keri Toner , MD
Children's National Hospital
Washington,  DC
Epstein-Barr Virus T Cell Immunity and Genetic Susceptibility

Fabian Frontzek
BC Cancer Research Centre
Vancouver,  BC, Canada
Epstein-Barr Virus + Diffuse Large B-cell Lymphoma – The Old and Not So Old

Moderator:

Rayne Rouce , MD
Texas Children's Hospital
Houston,  TX

Speakers:

Rayne Rouce , MD
Texas Children's Hospital
Houston,  TX
Moderator Introduction

Colm Keane , MD, PhD
The University of Queensland
Brisbane,  AUS
AIDS Related Central Nervous System Lymphomas – How Does Biology Inform Us?

Alexander Glover , mbchb
University of Birmingham
Nottingham,  United Kingdom
Chronic Active Epstein-Barr Virus - Are Myeloid Derived Suppressor Cells the Key?

Lisa Giulino Roth , MD
Weill Cornell Medical College
New York,  NY
Epigenetic Reprogramming to Sensitize Immunologically Silent EBV+ Lymphomas

Moderator:

Maher K. Gandhi , MBChB, PhD
Mater Research, University of Queensland
Brisbane,  QLD, Australia

Speakers:

Maher K. Gandhi , MBChB, PhD
Mater Research, University of Queensland
Brisbane,  QLD, Australia
Moderator Introduction

Joseph G Schroers-Martin , MD
Stanford University
Menlo Park,  CA
Post Transplant Lymphoproliferative Disorder and Its Ecosystem

Michael Boeckh , MD,PhD
Fred Hutchinson Cancer Center
Seattle,  WA
New Treatments for CMV Reactivation after Hematopoietic Stem Cell Transplant

Moderator:

Keri Toner , MD
Children's National Hospital
Washington,  DC

Speakers:

Keri Toner , MD
Children's National Hospital
Washington,  DC
Moderator Introduction

Spyridoula Vasileiou
Baylor College of Medicine
Houston,  TX
Restoration of Sars-COV-2-Specific T-Cell Immunity

Emily Blyth , MD,PhD
Westmead Hospital
Sydney,  Australia
Poly-Virus Specific T Cells As Prophylaxis Against BK, Vzv, CMV, EBV, Flu, Polyoma Virus and Fungal Infections after HSCT

Rayne Rouce , MD
Texas Children's Hospital
Houston,  TX
Trials and Tribulations - Autologous and 3rd Party EBV T Cell Immunotherapy

Moderator:

Rayne Rouce , MD
Texas Children's Hospital
Houston,  TX

65th ASH Annual Meeting Registration

San Diego Convention Center

Registration is now open for members, non-members, groups, exhibitors, and media!

View Registration Information